PDE4 Long-Form Activator Compounds for cAMP-Driven Cyst Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for structurally distinct small molecule activators of PDE4 long forms for therapeutic applications, as existing activators have not been reported in clinical development.
Innovation Solution
Development of novel compounds, represented by Formulas I to V, which selectively activate PDE4 long forms, offering potential therapeutic benefits by reducing excessive intracellular cAMP signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing PDE4 activators are used, then PDE4 activation is achieved, but structural diversity and therapeutic applicability are limited
Solution Approach 1:
The patent segments the PDE4 activator development into multiple distinct chemical series (Formula I, II, III, IV, V), each representing a different structural class. This segmentation allows exploration of diverse molecular architectures while maintaining the core PDE4 activation function, thereby improving therapeutic applicability without requiring a single complex molecule to achieve all desired properties.
Solution Approach 2:
The patent develops multiple structurally distinct small molecules that all share the universal function of activating PDE4 long forms. Each compound in the different formula series serves as a multi-functional agent that can activate PDE4 across various disease models (ADPKD, cardiac hypertrophy, inflammatory conditions), demonstrating universality in therapeutic application despite structural differences.
2Reliability
If PDE4 long forms are activated to reduce cAMP signaling, then therapeutic benefit is achieved, but selectivity over short forms must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that interact with unique regions of PDE4 long forms. The molecules are engineered to recognize and bind to the UCR1 and UCR2 regulatory regions that are present in long forms but absent in short forms, thereby achieving selective activation of long forms while leaving short forms unaffected, maintaining both efficacy and safety.
Solution Approach 2:
The patent employs small molecule intermediaries that act as selective activators by binding to specific regulatory sites on PDE4 long forms. These intermediary compounds mediate the activation process through allosteric mechanisms, distinguishing between long and short forms based on their structural differences, particularly the presence of UCR1 and UCR2 domains in long forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate selective activation of PDE4 long forms, reducing cAMP-driven cyst formation in ADPKD models, and are suitable for treating various diseases mediated by excessive cAMP signaling.
Implementation Method 1
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5′-AMP
Implementation Method 2
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5′-AMP
Data Source
AI summary
The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).